EUVIMEDScopri EUVIMED
Crossref

The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy

Eduardo Santos da Silva iD, Marina Borges Rabelo de Santana iD, Elisânia Fontes Silveira iD, Rogério Tanan Torres, Raphael Chagas Silva iD, Antônio Márcio Santana Fernandes iD, Emília Maria Medeiros de Andrade Belitardo iD, Luis Fabián Salazar Garcés iD, Leonardo Freire Santiago iD, Juan Ricardo Urrego, Deise Souza Vilas-Bôas, Luiz Antônio Rodrigues de Freitas and 8 more

Clinical & Experimental Allergy · 2023

DOI: 10.1111/cea.14293 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2023. Written by Eduardo Santos da Silva and 19 co-authors. Institution: Laboratory of Allergology and Acarology (LAA), Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil. Major MEDLINE topics: Hypersensitivity. Cited 7 times so far (Crossref); 63 references. Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado da Bahia.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Allergen‐specific immunotherapy (AIT) is the only disease‐modifying treatment approach to change disease‐causing allergens. Hypoallergenic derivatives show promise as potential therapeutics, amongst which BTH2 was designed to induce tolerance against Blomia tropicalis allergy. Our aim was to investigate the hypoallergenicity and immunoregulatory activity of BTH2 in vitro and its therapeutic potential in a mouse model of AIT.

Methods

Recombinant Blo t 5 and Blo t 21 allergens and their hybrid derivatives (BTH1 and BTH2) were expressed and purified. IgE binding capacity was tested by ELISA using sera from Brazilian, Colombian, and Ecuadorian subjects. Secretion of cytokines in supernatants from human cell cultures was measured following stimulation with the four recombinants and controls. The capacity of BTH2 to ameliorate allergic airway inflammation induced by B. tropicalis extract was evaluated in a murine model of AIT. Results rBlo t 5 and rBlo t 21 were identified as major allergens in Latin American patients, and BTH2 had the lowest IgE binding. In vitro stimulation of human cells induced greater levels of IL‐10 and IFN‐γ and reduced the secretion of Th2 cytokines. BTH2 ameliorated allergic airway inflammation in B. tropicalis ‐challenged A/J mice, as evidenced by the histopathological and humoral biomarkers: decreased Th2 cytokines and cellular infiltration (especially eosinophils), lower activity of eosinophil peroxidase, an increase in IgG blocking antibodies and strong reduction of mucus production by goblet cells.

Conclusions

Our study shows that BTH2 represents a promising candidate for the treatment of B. tropicalis allergy with hypoallergenic, immune regulatory and therapeutic properties. Further pre‐clinical studies are required in murine models of chronic asthma to further address the efficacy and safety of BTH2 as a vaccine against B. tropicalis ‐induced allergy.

Subjects

MeSH terms (MEDLINE)

HypersensitivityHumansMiceAnimalsDisease Models, AnimalAllergensInflammationCytokinesDesensitization, ImmunologicImmunoglobulin E

Author keywords

Blomia tropicalisallergen immunotherapyexperimental modelperipheral blood mononuclear cellvaccine candidate

Substances

AllergensCytokinesImmunoglobulin E

Authors and institutions

  • Laboratory of Allergology and Acarology (LAA), Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
  • Post-Graduate Program in Biotechnology of the Northeast Biotechnology Network (RENORBIO), Maceió, Brazil.
  • Post-Graduate Program in Immunology, Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil.
  • Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FioCruz), Salvador, Brazil.
  • Faculty of Health Sciences, Technical University of Ambato, Ambato, Ecuador.
  • Department of Pharmacy, University of Cartagena, Cartagena, Colombia.

ORCID profiles: Eduardo Santos da Silva, Marina Borges Rabelo de Santana, Elisânia Fontes Silveira, Raphael Chagas Silva, Antônio Márcio Santana Fernandes, Emília Maria Medeiros de Andrade Belitardo, Luis Fabián Salazar Garcés, Leonardo Freire Santiago, Josefina Zakzuk, Luis Gustavo Carvalho Pacheco, Fatima Ferreira, Philip Cooper, Carina da Silva Pinheiro, Neuza Maria Alcantara-Neves

Funding

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado da Bahia

Cite

APA

da Silva, E. S., de Santana, M. B. R., Silveira, E. F., Torres, R. T., Silva, R. C., Fernandes, A. M. S., Belitardo, E. M. M. A., Garcés, L. F. S., Santiago, L. F., Urrego, J. R., Vilas-Bôas, D. S., de Freitas, L. A. R., Zakzuk, J., Pacheco, L. G. C., Cruz, Á. A., Ferreira, F., Cooper, P., Caraballo, L., Pinheiro, C. D. S., & Alcantara-Neves, N. M. (2023). The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14293

Vancouver

da Silva ES, de Santana MBR, Silveira EF, Torres RT, Silva RC, Fernandes AMS, et al. The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14293

BibTeX
@article{daSilva2023,
  author = {da Silva, Eduardo Santos and de Santana, Marina Borges Rabelo and Silveira, Elisânia Fontes and Torres, Rogério Tanan and Silva, Raphael Chagas and Fernandes, Antônio Márcio Santana and Belitardo, Emília Maria Medeiros de Andrade and Garcés, Luis Fabián Salazar and Santiago, Leonardo Freire and Urrego, Juan Ricardo and Vilas-Bôas, Deise Souza and de Freitas, Luiz Antônio Rodrigues and Zakzuk, Josefina and Pacheco, Luis Gustavo Carvalho and Cruz, Álvaro Augusto and Ferreira, Fatima and Cooper, Philip and Caraballo, Luis and Pinheiro, Carina da Silva and Alcantara-Neves, Neuza Maria},
  title = {The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM ‐specific immunotherapy},
  journal = {Clinical & Experimental Allergy},
  year = {2023},
  doi = {10.1111/cea.14293}
}
Start for free →